Clinical Trials on Glomerulonephritis, IGA in Australia

Total 71 results

The George Institute
Peking University First Hospital

Completed

Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study) (TESTING)

IgA Glomerulonephritis

Canada, China, Australia, Malaysia, Hong Kong, India
Rigel Pharmaceuticals

Completed

Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy

IGA Nephropathy

United States, United Kingdom, Hong Kong, Taiwan, Austria, Germany
Eledon Pharmaceuticals

Terminated

Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)

IgA Nephropathy | IgAN

Australia, Spain, Thailand, New Zealand, Croatia, Malaysia, Philippines, Poland, Sri Lanka, United Kingdom
The George Institute
Peking University Institute of Nephrology

Recruiting

TESTING -ON Post-Trial ObservatioNal Cohort Study (TESTING-ON)

Kidney Diseases | Glomerulonephritis | ESRD | IgA Nephropathy

Australia, China, Canada, Hong Kong, India, Malaysia
Ionis Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Participants With Primary IgA Nephropathy

Primary IgA Nephropathy

Canada, Australia, New Zealand, Singapore
Novartis Pharmaceuticals

Completed

Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation

IgA Nephropathy

Colombia, Taiwan, Czechia, India, Turkey, Belgium, Netherlands, Singapore, Australia, Korea, Republic of, Thailand, Argentina, Germany, Israel, Japan, Sweden, United Kingdom, Brazil, China, Hong Kong, Norway, Finland, France, Denmark, M...
Novartis Pharmaceuticals

Recruiting

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

Primary IgA Nephropathy

Japan, Korea, Republic of, United States, Denmark, France, Taiwan, Belgium, Israel, Thailand, Germany, India, Czechia, Malaysia, Argentina, Singapore, China, Australia, Norway, Turkey, United Kingdom, Brazil, Hong Kong, Netherlands, C... and more
HI-Bio

Completed

Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy (IGNAZ)

Immunoglobulin A (IgA) Nephropathy

United Kingdom, Germany, Spain, Serbia, Taiwan, Australia, Japan, Korea, Republic of, Belgium, United States, Bulgaria, Czechia, Georgia, Malaysia, Philippines, Ukraine
Arrowhead Pharmaceuticals

Recruiting

Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease

IgA Nephropathy | C3 Glomerulopathy

New Zealand, Australia, Korea, Republic of, Thailand, Germany, United Kingdom, Georgia
Hoffmann-La Roche

Recruiting

A Study to Evaluate the Efficacy and Safety of RO7434656 in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression (IMAGINATION)

Primary IgA Nephropathy

Korea, Republic of, Australia, Spain, United Kingdom, Taiwan, China, Japan, France, United States, Italy, Greece, Czechia, Singapore, Argentina, Germany, Brazil, Poland, Canada
Visterra, Inc.

Completed

Safety and Efficacy Study of VIS649 for IgA Nephropathy

Immunoglobulin A Nephropathy | Glomerular Disease | IgAN

United States, Australia, Canada, Hong Kong, India, Japan, Korea, Republic of, Malaysia, Philippines, Singapore, Spain, Sri Lanka, Taiwan, Thailand, United Kingdom
Chinook Therapeutics, Inc.

Recruiting

Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy (ASSIST)

Immunoglobulin A Nephropathy | IgA Nephropathy

Spain, United States, Australia, Korea, Republic of, Brazil, Malaysia
Omeros Corporation

Terminated

Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy

IgA Nephropathy

United States, Argentina, Australia, Belgium, Bulgaria, Canada, Czechia, Germany, Greece, Hungary, India, Italy, Korea, Republic of, Lithuania, Poland, Singapore, Slovakia, Spain, Sweden, Taiwan, Thailand, Turkey, United Kingdom
Alexion Pharmaceuticals, Inc.

Recruiting

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) (ICAN)

Immunoglobulin A Nephropathy | IgAN

Spain, United Kingdom, United States, Italy, Korea, Republic of, Belgium, Germany, Colombia, Japan, China, France, Saudi Arabia, Thailand, Australia, Canada, Brazil, Malaysia, Poland, Taiwan, Austria, Greece, Israel, Netherlands, Arge... and more
Calliditas Therapeutics AB

Completed

Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy (Nefigard)

Primary IgA Nephropathy

United States, Australia, Taiwan, Spain, Canada, Argentina, Belarus, Belgium, Czechia, Finland, France, Germany, Greece, Italy, Korea, Republic of, Poland, Sweden, Turkey, United Kingdom
Chinook Therapeutics, Inc.

Recruiting

A Study of BION-1301 in Adults With IgA Nephropathy

Immunoglobulin A Nephropathy | IgA Nephropathy

United States, Canada, Australia, Argentina, Korea, Republic of
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients (APPLAUSE-IgAN)

IgA Nephropathy

United States, Taiwan, Czechia, Germany, Hungary, India, Turkey, Belgium, Netherlands, Singapore, Australia, Canada, Italy, Korea, Republic of, Spain, Thailand, Denmark, Slovenia, United Kingdom, Argentina, Brazil, Israel, Japan, France, Swed... and more
Chinook Therapeutics U.S., Inc.

Active, not recruiting

Atrasentan in Patients With IgA Nephropathy (ALIGN)

Immunoglobulin A Nephropathy | IgA Nephropathy

United States, Spain, Taiwan, Hong Kong, China, New Zealand, United Kingdom, Korea, Republic of, Canada, Australia, Germany, France, India, Japan, Argentina, Italy, Brazil, Colombia, Poland, Portugal
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN

C3 Glomerulopathy | C3 Glomerulonephritis | Dense Deposit Disease | Immune Complex Mediated Membranoproliferative Glomerulonephritis | Membranoproliferative Glomerulonephritis Types I, II, and III

Netherlands, Australia, Belgium
Alexion Pharmaceuticals, Inc.

Recruiting

Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

Lupus Nephritis | Immunoglobulin A Nephropathy | IgAN | LN

Australia, Spain, United Kingdom, China, Germany, Italy, Argentina, Peru, Korea, Republic of, Taiwan, Thailand, United States, Serbia, Israel, Brazil, Turkey, Mexico, Russian Federation
Travere Therapeutics, Inc.

Active, not recruiting

A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy (PROTECT)

Immunoglobulin A Nephropathy

United States, Australia, Belgium, Croatia, Czechia, Estonia, France, Germany, Hong Kong, Italy, Korea, Republic of, Lithuania, New Zealand, Poland, Portugal, Spain, Taiwan, United Kingdom
Alexion

Recruiting

Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) (SANCTUARY)

Lupus Nephritis | Immunoglobulin A Nephropathy

United States, Australia, Canada, France, Germany, Italy, Korea, Republic of, Netherlands, Poland, Singapore, Spain, Sweden, Taiwan, United Kingdom
The University of Queensland
University of Adelaide

Not yet recruiting

REmission in Membranous Nephropathy International Trial (REMIT) (REMIT)

Primary Membranous Nephropathy

Australia
Alpine Immune Sciences, Inc.

Recruiting

An Open-label Study of Povetacicept (ALPN-303) in Autoimmune Kidney Diseases (RUBY-3)

Lupus Nephritis | Immunoglobulin A Nephropathy | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Membranous Nephropathy

United States, Australia, Korea, Republic of, Austria, Norway, Spain, United Kingdom
Alexion

Terminated

A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471

IC-MPGN | C3 Glomerulopathy | C3 Glomerulonephritis | Dense Deposit Disease | Immune Complex Membranoproliferative Glomerulonephritis

United States, Australia, Belgium, Italy, Netherlands
Apellis Pharmaceuticals, Inc.

Active, not recruiting

Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN (NOBLE)

Renal Transplant | C3G | IC-MPGN | C3 Glomerulopathy | C3 Glomerulonephritis | Complement 3 Glomerulopathy | Complement 3 Glomerulopathy (C3G) | Complement 3 Glomerulonephritis | Membranoproliferative Glomerulonephritis | Membranoproliferative Glomerulonephritis (MPGN) | Immune Complex Membranoproliferative... and other conditions

United States, Australia, Austria, United Kingdom, Brazil, Argentina, France, Italy, Netherlands, Spain, Switzerland
Apellis Pharmaceuticals, Inc.

Active, not recruiting

An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis (VALE)

C3G | IC-MPGN | C3 Glomerulopathy | C3 Glomerulonephritis | Complement 3 Glomerulopathy | Complement 3 Glomerulopathy (C3G) | Complement 3 Glomerulonephritis | Dense Deposit Disease | DDD | Membranoproliferative Glomerulonephritis | Membranoproliferative Glomerulonephritis (MPGN) | Immune Complex Membranoproliferative...

United States, Australia, Brazil, Czechia, France, Italy, Korea, Republic of, Netherlands, Spain, Switzerland, United Kingdom
Apellis Pharmaceuticals, Inc.

Active, not recruiting

Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis (VALIANT)

C3G | IC-MPGN | C3 Glomerulopathy | C3 Glomerulonephritis | Complement 3 Glomerulopathy | Complement 3 Glomerulopathy (C3G) | Complement 3 Glomerulonephritis | Dense Deposit Disease | DDD | Membranoproliferative Glomerulonephritis | Membranoproliferative Glomerulonephritis (MPGN) | Immune Complex Membranoproliferative...

United States, Spain, France, Germany, United Kingdom, Netherlands, Brazil, Israel, Japan, Australia, Austria, Italy, Switzerland, Korea, Republic of, Czechia, Belgium, Argentina, Canada, Poland
Chinook Therapeutics U.S., Inc.

Active, not recruiting

Atrasentan in Patients With Proteinuric Glomerular Diseases (AFFINITY)

Diabetic Kidney Disease | Focal Segmental Glomerulosclerosis | Immunoglobulin A Nephropathy | IgA Nephropathy | Diabetic Nephropathy Type 2 | Alport Syndrome

United States, Spain, Korea, Republic of, Australia, Italy, United Kingdom
Melbourne Health

Completed

Using the Drug Spironolactone to Test If It Reduces Protein Leakage From the Kidney

Diabetic Nephropathy | Proteinuria | Glomerulonephritis | Kidney Disease

Australia
Dimerix Bioscience Pty Ltd
Iqvia Pty Ltd

Completed

Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesartan (ACTION)

Focal Segmental Glomerulosclerosis

Australia
GlaxoSmithKline

Withdrawn

Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy

Glomerulonephritis, Membranous

Australia, Spain, United States, Canada, Germany, Netherlands, France, United Kingdom, Czech Republic, Italy
HI-Bio

Completed

Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) (M-PLACE)

Glomerulonephritis, Membranous | antiPLA2R Positive

Spain, Belgium, Australia, Italy, United States, Korea, Republic of, France, Netherlands, Poland
La Jolla Pharmaceutical Company

Completed

Safety and Efficacy Study of LJP 394 (Abetimus Sodium) to Treat Lupus Kidney Disease

Autoimmune Diseases | Systemic Lupus Erythematosus | Lupus Nephritis | Immunologic Diseases | Lupus Glomerulonephritis

United States, Austria, Canada, France, Germany, Italy, Mexico, Spain, Sweden, United Kingdom
Baxalta now part of Shire

Terminated

Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis

Systemic Lupus Erythematosus

Australia, United States, New Zealand, Mexico, Canada
Medical University of Vienna
Medical University of Graz; Radboud University Medical Center; Charite University... and other collaborators

Terminated

TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL )

Lupus Erythematosus, Systemic | Lupus Nephritis

Austria, Germany, Netherlands
Christoph Aufricht

Recruiting

ARREST-NEPHROSIS - Austrian Resistant Nephrotic Syndrome Treatment Response Registry and Biobank

Proteinuria | Focal Segmental Glomerulosclerosis | Nephrotic Syndrome | Nephrotic Syndrome Steroid-Resistant

Austria
ImmPACT Bio

Recruiting

A Study of IMPT-514 in Active Refractory Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus | Lupus Nephritis

United States, Australia
BioMarin Pharmaceutical

Completed

BMN 110 Phase 3B in Australian Patients (MOR-AUS)

Mucopolysaccharidosis IVA (Morquio A Syndrome)

Australia
HI-Bio

Recruiting

A Study of Felzartamab in Participants With Lupus Nephritis

Lupus Nephritis

United States, Argentina, Australia
Novartis Pharmaceuticals

Recruiting

An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus

Systemic Lupus Erythematosus | Lupus Nephritis

Spain, Switzerland, Germany, Australia, France, United States
Boehringer Ingelheim

Completed

An Exploratory Maintenance Trial of BI 655064 in Patients With Lupus Nephritis

Lupus Nephritis

United Kingdom, Thailand, Germany, Japan, United States, Australia, Korea, Republic of, Hong Kong, Poland, Greece, Mexico, Czechia, Canada, Malaysia, Philippines, Portugal
Takeda

Active, not recruiting

A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy

Glomerulonephritis | Kidney Disease

Taiwan, Australia, Hungary, Spain, United Kingdom, United States, China, Korea, Republic of, Italy, Japan, Singapore
Mårten Segelmark
Hansa Biopharma AB

Completed

Open-Label Phase II Study to Evaluate the Efficacy and Safety of IdeS in Anti-GBM Disease (GOOD-IDES-01)

Anti-Glomerular Basement Membrane Antibody Disease

Austria, Czechia, Denmark, France, Sweden
Bristol-Myers Squibb

Terminated

An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis

Lupus Nephritis

United States, Taiwan, Spain, United Kingdom, Netherlands, Germany, China, Australia, Belgium, Mexico, Korea, Republic of, Czechia, Russian Federation, Israel, Canada, Italy
Biogen

Terminated

BIIB023 Long-Term Extension Study in Subjects With Lupus Nephritis

Lupus Nephritis

Belgium, Peru, Italy, Malaysia, Australia, Argentina, United States, Hong Kong, Hungary, Poland, Colombia, Russian Federation, Philippines, Brazil, France, Korea, Republic of, Mexico, Spain, Thailand
Bristol-Myers Squibb

Terminated

Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis

Lupus Nephritis

Australia, China, Italy, Taiwan, Turkey, United States, Hong Kong, Spain, Russian Federation, Korea, Republic of, Japan, Israel, Romania, Puerto Rico, Argentina, Brazil, Canada, Chile, Colombia, Czechia, India, Mexico, Peru
Ipsen

Recruiting

Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

IGF1 Deficiency

Spain, United States, Italy, France, United Kingdom, Germany, Austria, French Guiana, Poland, Sweden, Martinique
ChemoCentryx
Medpace, Inc.

Completed

A Study of CCX140-B in Subjects With FSGS

Focal Segmental Glomerulosclerosis | FSGS | Glomerulosclerosis

United States, France, Italy, Australia, United Kingdom, Canada, New Zealand, Poland
Mallinckrodt ARD LLC

Completed

Acthar for Treatment-Resistant or Treatment-Intolerant Proteinuria (PODOCYTE)

Idiopathic Focal Segmental Glomerulosclerosis

United States, Argentina, Turkey, Peru, Australia, Chile, Mexico

Clinical Trials on Glomerulonephritis, IGA in Australia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations